Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 3:11:1-21.
doi: 10.1016/j.ncrna.2024.11.006. eCollection 2025 Apr.

Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications

Affiliations
Review

Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications

Mehrdad Hashemi et al. Noncoding RNA Res. .

Abstract

Lung cancer (LC) is one of the most common causes of cancer-related death worldwide. It has been demonstrated that the prognosis of current drug treatments is affected by a variety of factors, including late stage, tumor recurrence, inaccessibility to appropriate treatments, and, most importantly, chemotherapy resistance. Non-coding RNAs (ncRNAs) contribute to tumor development, with some acting as tumor suppressors and others as oncogenes. The phosphoinositide 3-kinase (PI3Ks)/AKT serine/threonine kinase pathway is one of the most important common targets of ncRNAs in cancer, which is widely applied to modulate the cell cycle and a variety of biological processes, including cell growth, mobility survival, metabolic activity, and protein production. Discovering the biology of ncRNA-PI3K/AKT signaling may lead to advances in cancer diagnosis and treatment. As a result, we investigated the expression and role of PI3K/AKT-related ncRNAs in clinical characteristics of lung cancer, as well as their functions as potential biomarkers in lung cancer diagnosis, prognosis, and treatment.

Keywords: Lung cancer; Molecular mechanisms; Non-coding RNAs; PI3K; Signaling pathway.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
A schema of the PI3K/AKT/mTOR signaling pathway.
Fig. 2
Fig. 2
Schematic view of the various isoforms of the PI3K/AKT/mTOR signaling pathway. Each isoform plays a distinct role in cellular processes, including growth, proliferation, and survival. Understanding these isoforms is crucial for elucidating their contributions to cancer biology and therapeutic targeting.
Fig. 3
Fig. 3
This schematic illustrates the downstream pathways influenced by AKT activation. It highlights the critical signaling cascades that are modulated upon AKT activation, providing insight into their roles in cellular processes such as growth, survival, and metabolism.
Fig. 4
Fig. 4
Schematic view of the relationship between ncRNAs and LC cell proliferation and apoptosis via the PI3K signaling pathway. It highlights how ncRNAs can modulate key components of the PI3K pathway, thereby influencing cellular processes such as growth, proliferation, and apoptosis. Understanding these interactions is vital for elucidating the regulatory mechanisms underlying lung cancer progression and identifying potential therapeutic targets.
Fig. 5
Fig. 5
Schematic view of the relationship between ncRNAs and the LC cell progression, invasion, and migration via the PI3K signaling pathway. It emphasizes the roles of lncRNAs, circRNAs, and miRNAs in regulating key elements of the PI3K pathway, thereby influencing critical processes associated with tumor advancement. By modulating gene expression and signaling cascades, these ncRNAs contribute to the metastatic potential of lung cancer cells.
Fig. 6
Fig. 6
Schematic view of the relationship between ncRNAs and the EMT process in LC drug resistance via the PI3K signaling pathway.

Similar articles

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2018;68(6):394–424. - PubMed
    1. Araghi M., Mannani R., Heidarnejad maleki A., Hamidi A., Rostami S., Safa S.H., et al. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 2023;23(1):162. - PMC - PubMed
    1. Azizi M., Othman I., Naidu R. The role of MicroRNAs in lung cancer metabolism. Cancers. 2021;13(7) - PMC - PubMed
    1. Kahkesh S., Khoshnazar S.M., Gholinezhad Y., Esmailzadeh S., Hosseini S.A., Alimohammadi M., et al. The potential role of circular RNAs -regulated PI3K signaling in non-small cell lung cancer: molecular insights and clinical perspective. Pathol. Res. Pract. 2024;257 - PubMed
    1. Lemjabbar-Alaoui H., Hassan O.U., Yang Y.-W., Buchanan P. Lung cancer: biology and treatment options. Biochim. Biophys. Acta Rev. Canc. 2015;1856(2):189–210. - PMC - PubMed

LinkOut - more resources